Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
Hidetoshi Hayashi(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Akira Ono(Shizuoka Cancer Center), Nobuaki Matsubara(National Cancer Center Hospital East), Kazuko Sakai(Kindai University Sakai Hospital), Koji Takeda(NewYork–Presbyterian Hospital), Yuichi Takiguchi(Sanno Medical Center), Takuma Onoe(Hyogo Prefectural Cancer Center), Masanori Toyoda(Kobe University), Yasuhiro Koh(Wakayama Medical University), Takayasu Kurata(Kansai Medical University), Yusuke Onozawa(Shizuoka Cancer Center), Koji Matsumoto(Showa University), Ayano Takeuchi(Keio University), Hironobu Minami(Kobe University), Hirofumi Mukai(National Cancer Center Hospital East), Yasuo Ohashi(Chuo University), Makoto Arai(Chiba University), Yoshihiko Fujita(Kyoto University), Kohei Akiyoshi(Osaka City General Hospital), Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 168
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k